<DOC>
	<DOCNO>NCT01954043</DOCNO>
	<brief_summary>The study conduct evaluate effect rifampin ( strong CYP3A4 inducer ) rabeprazole ( pH elevate agent ) PK dabrafenib ( CYP3A4/CYP2C8 substrate ) . The study conduct subject BRAF V600 mutation-positive tumor . Data collect study use inform recommendation regard use concomitant medication dabrafenib future clinical pharmacologic evaluation dabrafenib .</brief_summary>
	<brief_title>A Pharmacokinetics ( PK ) Study Effects Rabeprazole Rifampin Dabrafenib Subjects With BRAF V600 Mutation Positive Tumors</brief_title>
	<detailed_description />
	<mesh_term>Rabeprazole</mesh_term>
	<mesh_term>Rifampin</mesh_term>
	<mesh_term>Dabrafenib</mesh_term>
	<criteria>Male female least 18 year age time sign informed consent form . Provided sign write informed consent . Capable compliance requirement restriction list consent form . Body weight &gt; =45 kilogram ( kg ) body mass index ( BMI ) &gt; =19 Kilogram per meter square ( kg/m^2 ) &lt; 40 kg/m^2 ( inclusive ) . Able swallow retain oral medication . BRAF V600 mutationpositive tumor confirm Clinical Laboratory Improvement Amendments ( CLIA ) approve laboratory equivalent . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . Adequate baseline organ function define study protocol . Women childbearing potential must willing practice acceptable method birth control . Additionally , woman childbearing potential must negative serum pregnancy test within 14 day prior first dose study medication . History another malignancy exception , malignancy confirm activate RAS mutation . Exception : ( ) Subjects successfully treat diseasefree 5 year , ( b ) history completely resect nonmelanoma skin cancer , ( c ) successfully treat situ carcinoma , ( ) CLL stable remission , ( e ) indolent prostate cancer ( definition : clinical stage T1 T2a , Gleason score &lt; =6 , PSA &lt; 10 nanogram per milliliter [ ng/mL ] ) require antihormonal therapy , eligible . Cancer therapy ( chemotherapy delay toxicity , extensive radiation therapy , immunotherapy , biologic therapy , major surgery ) investigational anticancer drug within last 3 week , chemotherapy without delayed toxicity within last 2 week , precede first dose dabrafenib . Unresolved toxicity great Grade 2 previous anticancer therapy except alopecia . Any serious and/or unstable preexist medical , psychiatric disorder condition could interfere subject 's safety , obtain informed consent compliance study procedure . Current use therapeutic warfarin . Any prohibited medication ( ) herbal preparation describe study protocol require medication study . Have know immediate delay hypersensitivity reaction idiosyncrasy drug chemically relate dabrafenib , rabeprazole rifampin , excipients contraindicate participation . Pregnant nursing female . A history evidence cardiovascular risk include follow : QT interval correct heart rate use Bazett 's formula ( QTcB ) &gt; =480 millisecond ( msec ) ; history evidence current clinically significant uncontrolled arrhythmia ; history acute coronary syndrome ( include myocardial infarction unstable angina ) , coronary angioplasty , stenting within 6 month prior randomization ; history evidence current &gt; =Class II congestive heart failure ( CHF ) define New York Heart Association ( NYHA ) guideline ; Abnormal cardiac valve morphology ( &gt; =grade 2 ) document echocardiogram ( subject grade 1 abnormality [ i.e. , mild regurgitation/stenosis ] enter study ) . Subjects moderate valvular thickening enter study . Presence active gastrointestinal ( GI ) disease condition ( e.g. , small bowel large bowel resection ) interfere significantly absorption drug . If clarification need whether condition significantly affect absorption drug , contact GSK Medical Monitor . A history know Human Immunodeficiency Virus ( HIV ) , Hepatitis B Virus , Hepatitis C Virus infection . Subjects brain metastasis exclude brain metastasis : Symptomatic , Treated ( surgery , radiation therapy ) clinically radiographically stable one month local therapy , asymptomatic untreated &gt; 1 centimeter ( cm ) long dimension . Subjects small ( &lt; =1 cm long dimension ) , asymptomatic brain metastasis need immediate local therapy enrol . Subjects stable dose corticosteroid &gt; 1 month , corticosteroid least 2 week enrol . Subjects must also enzymeinducing anticonvulsant 4 week .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>melanoma</keyword>
	<keyword>dabrafenib</keyword>
	<keyword>BRAF V600</keyword>
	<keyword>rabeprazole</keyword>
	<keyword>rifampin</keyword>
</DOC>